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Background: Probing genetic dependencies of cancer cells can improve our understanding of tumour 
development and progression, as well as identify potential drug targets. CRISPR-Cas9-based and shRNA- 
based genetic screening are commonly utilized to identify essential genes that affect cancer growth. How- 
ever, systematic methods leveraging these genetic screening techniques to derive consensus cancer de- 
pendency maps for individual cancer cell lines are lacking. 
Finding: In this work, we ﬁrst explored the CRISPR-Cas9 and shRNA gene essentiality proﬁles in 42 can- 
cer cell lines representing 10 cancer types. We observed limited consistency between the essentiality pro- 
ﬁles of these two screens at the genome scale. To improve consensus on the cancer dependence map, we 
developed a computational model called combined essentiality score (CES) to integrate the genetic essen- 
tiality proﬁles from CRISPR-Cas9 and shRNA screens, while accounting for the molecular features of the 
genes. We found that the CES method outperformed the existing gene essentiality scoring approaches in 
terms of ability to detect cancer essential genes. We further demonstrated the power of the CES method 
in adjusting for screen-speciﬁc biases and predicting genetic dependencies in individual cancer cell lines. 
Interpretation: Systematic comparison of the CRISPR-Cas9 and shRNA gene essentiality proﬁles showed 
the limitation of relying on a single technique to identify cancer essential genes. The CES method provides 
an integrated framework to leverage both genetic screening techniques as well as molecular feature data 
to determine gene essentiality more accurately for cancer cells. 
© 2019 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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2. Introduction 
Interrogating the genetic dependencies of cancer cells provides
mportant evidence for target-based drug discovery [1] . Loss-of-
unction screens have emerged as powerful tools to introduce ge-
etic perturbations in vitro , providing new opportunities to identify
enes that are essential for cell survival and proliferation [2] . To
arry out a systematic exploration of genome-scale cancer depen-
ency proﬁles, these genetic screens rely on a library containing
arious synthetized short sequence constructs designed to target
peciﬁc genes. Using an optimized delivery system, the library as a
hole can be eﬃciently introduced into a cell culture, resulting in
 mixture of cell subpopulations, each carrying one sequence con-
truct that triggers the depletion of a particular gene. During the∗ Corresponding author. 
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cancer dependency maps, EBioMedicine, https://doi.org/10.1016/j.ebiomulture period, the cell subpopulations depleted of essential genes
ill lose ﬁtness, resulting in under-representation of their effector
equence constructs [3] . To quantify the degree of essentiality for
ndividual genes (i.e. the gene essentiality score), genomic DNA is
solated from the cell culture both at the initial condition and at
he end of the culture period. Using PCR and next-generation se-
uencing technologies, depletion of corresponding sequence con-
tructs can be determined subsequently. 
Over the last decade, short hairpin RNA (shRNA), together with
he more recently developed CRISPR-Cas9-based sgRNA (single
uide RNA) have been adopted as two major techniques to con-
uct genome-scale loss-of-function screens. The shRNA-based and
RISPR-based screens involve construction of synthetic oligonu-
leotide sequences that are delivered into cells to activate distinct
oss-of-function machineries: shRNA is directed to bind to its target
RNA in the cytoplasm via the RNAi (RNA interference) path-
ay, leading to degradation of the target mRNA and loss of genexpression without altering the genome of the cells (i.e. a transient 
nder the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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Research in context 
Evidence before this study 
Interrogating the genetic dependencies of cancer cells pro- 
vides important evidences for target-based drug discovery. 
RNAi-based shRNA and CRISPR-Cas9-based sgRNA have been 
commonly utilized in functional genetic screens to derive 
cancer dependence maps. However, previous studies sug- 
gested limited overlap of essentiality proﬁles based on the 
two technologies. Existing computational methods mainly fo- 
cused on estimation of true gene essentiality from genetic 
screens using single technologies, but integrative methods to 
combine the gene essentiality proﬁles from both CRISPR and 
shRNA screens are lacking. 
Added value of this study 
In the current study, we developed a computational approach 
called combined gene essentiality score (CES) to integrate 
CRISPR and shRNA gene essentiality proﬁles and the molecu- 
lar features of cancer cells. We showed that CES signiﬁcantly 
improved the performance of gene essentiality prediction for 
shared genetic dependencies across multiple cell lines as well 
as for therapeutic targets that are selective for a speciﬁc can- 
cer cell line. 
Implications of all the available evidence 
The CES approach provides an effective data integration 
strategy to allow improved estimation of cancer dependency 
maps, which may facilitate the discovery of therapeutic 
targets for personalized medicine. Although we have focused 
on the genetic screens that are largely restricted for the 
cell growth phenotype, the CES modelling strategy itself is 
applicable to interrogate genes that are essential for other 
image-based or antibody-based phenotypes, thus further 
accelerating the translation from biomedical discoveries to 
novel therapeutic development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
g  
c  
p  
w  
t
 
C  
m  
r  
i  
n  
C  
c  
t  
e  
c  
a  
e  
b  
v  
a  
t  
l  
b  
t  
i  
e  
n  
c
 
C  
c  
s  
a  
s  
b  
g  
c  
m  
d  
t  
t  
p  
t  
T  
/
2
2
 
s  
s  
t  
C  
c  
s  
e  
g  
m  
e  
i  
s  
M  
p  knockdown effect). In contrast, sgRNA utilizes the CRISPR pathway
to direct the Cas9 protein to cut genomic DNA in the nucleus, trig-
gering the non-homologous end joining (NHEJ) pathway to intro-
duce permanent loss-of-function mutations, which result in com-
plete and permanent knockout of the target genes [2,4,5] . Despite
the relative simplicity in experimental setups, the eﬃciency and
speciﬁcity of shRNA and sgRNA constructs need to be optimized
for reliable detection of cancer essential genes. For example, ev-
idence suggests that both shRNAs and sgRNAs may affect addi-
tional off-target genes due to partial sequence complementarity,
and therefore introduce experimental noise that masks the actual
cellular response to the intended gene depletions [1,6] . Differences
in gene-depletion eﬃciency may also contribute to the experimen-
tal variability in shRNA screens [7] as well as CRISPR-Cas9 screens
[8] . To optimize the design of the sequence library, computational
methods have been developed to predict the on-target eﬃciency
and off-target activity of shRNA or sgRNA sequences [8–10] . 
To further improve the accuracy of functional genetic screens,
another class of computational methods has focused on the esti-
mation of true gene essentiality from noisy experimental results,
while accounting for confounding factors. For example, recent pub-
lications have reported that increased genomic ampliﬁcation and
TP53 mutation status may confound the gene essentiality estimates
in CRISPR screens [11–14] . A computational method called CERES
has been developed to adjust for the inﬂated essentiality scores ofPlease cite this article as: W. Wang, A. Malyutina and A. Pessia et al.
cancer dependency maps, EBioMedicine, https://doi.org/10.1016/j.ebiomenes in genomic ampliﬁcation regions [11] . On the other hand,
omputational methods including DEMETER [15] have been pro-
osed to adjust the off-target effects mediated by micro-RNA path-
ays, which are known to be more prominent in shRNA screens
han in CRISPR screens. 
With the increasing maturity and wide application of both
RISPR and shRNA screening technologies, attempts have been
ade to integrate their gene essentiality proﬁles in order to de-
ive a more unbiased cancer dependence map [16–18] . However, it
s reported that the identiﬁed essential genes from the two tech-
iques overlapped only partially. Two recent studies carried out
RISPR and shRNA screens in parallel for several human cancer
ell lines [4,19] , with different conclusions being made in terms of
he accuracy for detecting truly essential genes. For example, Evers
t al. reported a superior prediction accuracy with CRISPR screens
ompared to shRNA screens [19] , whereas Morgens et al. observed
 similar level of prediction performance [4] . However, Morgens
t al. showed that a large proportion of essential genes identiﬁed
y CRISPR screens were not replicated in shRNA screens and vice
ersa, suggesting the presence of complex confounding factors that
re inherently distinct between these two technologies. Moreover,
hese comparative studies were conducted on a few genes and cell
ines; therefore, it remains unclear whether their conclusions can
e generalized. For example, Evers et al. investigated the essen-
iality proﬁles for a set of 46 essential and 47 non-essential genes
n two cancer cell lines (RT-112 and UM-UC-3), whereas Morgens
t al. analysed a larger gene set including 217 essential and 947
on-essential genes, but the comparison was made using only one
ell line, K562. 
In this study, we carried out a systematic comparison for
RISPR- and shRNA-based gene essentiality proﬁles across a larger
ollection of cancer cell lines. We found that the CRISPR and
hRNA-based gene essentiality proﬁles showed limited consistency
t the genome-wide level. To improve the estimation of true es-
entiality, we developed a computational approach called com-
ined gene essentiality score (CES) to integrate CRISPR and shRNA
ene essentiality proﬁles as well as the molecular features of can-
er cells. We showed that CES signiﬁcantly improved the perfor-
ance of gene essentiality prediction for shared genetic depen-
encies across multiple cell lines as well as for therapeutic targets
hat are selective for a speciﬁc cancer cell line. The CES approach
hus provides an effective data integration strategy to allow im-
roved estimation of cancer dependency maps, which may facili-
ate the discovery of therapeutic targets for personalized medicine.
he source code to replicate this analysis is available at https:
/github.com/Wenyu1024/CES . 
. Materials and methods 
.1. Data collection 
A total of 42 cancer cell lines with both CRISPR and shRNA
creenings performed at the genome-scale were included for the
tudy. CRISPR-based gene essentiality scores were obtained from
he Achilles study (v3.38) [12] and three other studies [20–22] .
RISPR-based gene essentiality scores were determined from their
orresponding level essentiality depletion scores using different
trategies. For example, the Achilles study used the second-top
ssential sgRNA depletion score to represent the CRISPR-based
ene essentiality, whereas the other studies utilized either arith-
etic averaging [21] or a Bayesian modelling averaging strat-
gy [20,22,23] . On the other hand, shRNA-based gene essential-
ty scores were obtained by arithmetic averaging over multiple
hRNA-level depletion scores from the Achilles study (v2.20) [15] .
olecular features for these cell lines including mutation, gene ex-
ression, and copy number variation were obtained from the Can-, Combined gene essentiality scoring improves the prediction of 
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Fig. 1. The CES data integration pipeline to improve identiﬁcation of cancer essential genes based on functional genetic screens and molecular feature data. Genome-wide 
shRNA and CRISPR-Cas9 based essentiality scores as well as molecular proﬁles for each cell line were obtained from public databases and literature. For a gene in a given 
cell line, a feature vector was constructed including CRISPR-based essentiality scores, shRNA-based essentiality scores, as well as mutation count, RPKM from RNA-seq, mRNA 
expression from microarray, and copy number variation. The aim of CES is to provide a data integration model to improve the consensus estimation of essential genes in 
cancer. 
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w  er Cell Line Encyclopaedia (CCLE) database [24] . More speciﬁcally,
oint mutations and indels were captured by targeted massively
arallel sequencing and were transformed into mutation counts for
ndividual genes. Gene expression features were represented via
he RNA-Seq-based RPKM counts and Affymetrix array-based log2
ntensity values, whereas the normalized log2 ratios of CN/2 from
ffymetrix SNP array were utilized as copy number variations. The
esulting data matrix thus contained the shRNA-based and CRISPR-
ased essentiality scores, as well as the molecular proﬁles for each
ene in a given cell line ( Fig. 1 ). All the features were normalized
s z-scores at each cell line for further analyses, resulting in a data
atrix with 16,492 genes for a total of 42 cell lines. A detailed list
f the data sources can be found in Supplementary Table 1. 
.2. Comparison of shRNA and CRISPR-based essentiality scores 
We ﬁrst ran a genome-wide comparison between shRNA- and
RISPR-based essentiality scores on the 42 cancer cell lines. We
ollowed the convention that has been adopted in major computa-
ional methods including DEMETER and CERES, where a lower and
ore negative essentiality score results from greater depletion of
ancer cells upon genetic perturbation and thus represents higher
ssentiality. Pearson correlation was employed to investigate the
onsistency between shRNA and CRISPR scores, where a higher
orrelation indicated better between-screen consistency whereas a
ero or negative correlation indicated poor between-screen consis-
ency. We also used the mean squared error (MSE) between shRNA
nd CRISPR essentiality scores to evaluate their consistency. 
.3. The CES model to integrate functional screen and molecular 
eature data 
We proposed a combined essentiality score (CES) that in-
egrates CRISPR and shRNA-based gene essentiality scores and
olecular features. Speciﬁcally, for a gene i, i = 1 , . . . , M in cell
ine j, j = 1 , . . . , N, the CES can be determined as 
E S i j = β j + θs shRN A i j + θm MU T i j + θc CN V i j 
+ θa EXP . arra y i j + θr EXP . RNAse q i j , (1) 
i j = 
CE S i j − CRISP R i j 
shRN A i j − CRISP R i j 
= β j + θs shRN A i j + θm MU T i j + θc CN V i
shRNPlease cite this article as: W. Wang, A. Malyutina and A. Pessia et al.
cancer dependency maps, EBioMedicine, https://doi.org/10.1016/j.ebiomhere the parameters in Eq. (1) are determined by minimizing the
ollowing objective function: 
M 
 
i =1 
N ∑ 
j=1 
(
CE S i j − CRISP R i j 
)2 
(2) 
To solve the linear least squares problem, a QR decomposition
lgorithm is utilized [25] . 
The CES deﬁned in Eq. (1) can be rewritten as a weighted aver-
ge of CRISPR- and shRNA-based gene essentiality scores, 
E S i j = 
(
1 − αi j 
)
CRISP R i j + αi j shRN A i j , (3) 
here the weight αij is affected by the molecular features as 
 
Exp . arra y i j + θr EXP . RNAse q i j − CRISP R i j 
CRISP R i j 
(4) 
Note that Eq. (3) does not imply that CES is a linear combina-
ion of CRISPR and shRNA scores; rather, their relationship is af-
ected by molecular features that are gene- and cell-line-speciﬁc,
hich can be captured in the model. 
.4. Model comparison 
We compared the CES model using three baseline models, in-
luding: 
1) SA: a simple averaging model, where αi j = 0 . 5 , i.e. 
S A i j = 
(
CRISP R i j + shRN A i j 
)
2 
(5) 
2) CES null : a CES model where the molecular signature infor-
mation is removed from Eq. (1) , i.e. 
CES null i j = β j + θs shRN A i j (6) 
3) CES perm : a CES model in which the molecular signatures are
randomly shuﬄed, i.e. 
CES perm 
i j 
= β j + θs shRN A i j + θm MU T i ∗ j ∗ + θc CN V i ∗ j ∗
+ θa EXP . arra y i ∗ j ∗ + θr EXP . RNAse q i ∗ j ∗ (7) 
here i ∗, j ∗ refer to a gene and a cell line that are randomly se-
ected to be different from ( i, j ) . 
The SA model was considered as a baseline as it assigns equal
eights to the CRISPR and shRNA-based screens, assuming that, Combined gene essentiality scoring improves the prediction of 
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dtheir gene essentiality proﬁles are generated from the same dis-
tribution. The CES null and CES perm models were used to evaluate the
relevance of molecular features. Namely, if molecular signatures of
a cell line play signiﬁcant roles in deﬁning true gene essential-
ity, then the CES model should perform better than the CES null and
CES perm models that contain null or randomized molecular infor-
mation. 
Furthermore, we compared the CES model with the CERES
model [11] , DEMETER1 model [15] , and DEMETER2 model [17] . The
CERES model estimated the gene essentiality score g ij by correcting
for the bias of gene copy numbers in CRISPR screens at the sgRNA
level. Namely, the observed depletion score D kj for a sgRNA k in
cell line j can be modelled as a linear function of the gene knock-
out effect h i + g i j and copy number effect f j ( 
∑ 
l∈ L k C l j ) , as well as
the sgRNA-speciﬁc error term o k and random noise : 
D k j = 
( ∑ 
i ∈ G k 
(
h i + g i j 
)
+ f j 
( ∑ 
l∈ L k 
C l j 
) ) 
+ o k +  (8)
The DEMETER1 model estimates the gene essentiality score by
adjusting for the off-target effect of shRNAs based on seed com-
plementarity, i.e. the observed depletion score H kj for a shRNA k in
cell line j can be decomposed into a sum of the gene knock-down
effect G lj and seed-speciﬁc effect S bj : 
H k j = 
∑ 
b∈ seed ( k ) 
αkb S b j + 
∑ 
l∈ gene ( k ) 
βkl G l j + μk + k j (9)
The DEMETER2 model extends the DEMETER1 model by includ-
ing the shRNA on-target eﬃcacy t k , off-target eﬃcacy e k , the screen
signal parameter for cell line q j , and additional off-target effect c k .
Furthermore, additional parameters a j , θ j , and γ j were used to cor-
rect the additional batch effects for the given cell line j : 
H k j = a j + θ j + γ j 
( 
q j t k 
∑ 
l∈ gene ( k ) 
βkl G l j + e k 
∑ 
b∈ gene ( k ) 
αkb S b j + c k 
) 
+k j
(10)
Note that the CERES model aimed at adjusting confounding fac-
tors in the CRISPR screen, whereas the DEMETER 1 and 2 models
aimed at improving target speciﬁcity in the shRNA screens. Both
methods combine the depletion scores at the shRNA or sgRNA level
to infer gene essentiality scores. In contrast, the CES model in-
tended to derive a gene essentiality score by combining the unad-
justed depletion scores at the gene level, as well as the molecular
features of cancer cells. Therefore, DEMETER1/2 and CERES repre-
sent screen-speciﬁc adjustment methods, whereas CES should be
considered as a data integration method that utilizes gene-level
data from both CRISPR and shRNA screens as well as from molec-
ular proﬁling. Despite the different techniques and data sources
used in these computational models, they shared the same pur-
pose of improving gene essentiality prediction, the performance of
which can be evaluated using the method below. 
2.5. Use of ground truth gene sets for model evaluation 
The CES model was compared with screen-speciﬁc methods, in-
cluding CRISPR (with or without the CERES adjustment), shRNA
(with or without the DEMETER adjustment), as well as the base-
line methods including SA, CES null and CES perm . For each method, a
gene essentiality score can be predicted for a given gene in a cell
line, based on which the ranking of the gene in this cell line can
be determined. The average ranking of the gene across all 42 cell
lines was considered as the overall essentiality score. Please cite this article as: W. Wang, A. Malyutina and A. Pessia et al.
cancer dependency maps, EBioMedicine, https://doi.org/10.1016/j.ebiomTo evaluate the accuracy of overall essentiality, the ground
ruth of true essential genes and non-essential genes was needed.
or cancer essential genes, we looked at three datasets includ-
ng i) 3804 housekeeping genes curated by Eisenberg et al. [26] ,
i) 360 common essential genes curated by Hart et al. [20] and
ii) 31 PanCancer oncogenes curated by Bailey et al. [27] (Sup-
lementary Tables 2–4). As the overlap between these three gene
ets is limited, we considered them separately when evaluating
odel performance (Supplementary Figure 1). For negative gene
ets, we used the 927 common non-essential genes curated by
art et al. [28] (Supplementary Table 5) along with the 75 Pan-
ancer tumour suppressor genes curated by Bailey et al. [27] (Sup-
lementary Table 6). We removed ambiguous genes that were in-
luded in both cancer essential genes and cancer non-essential
enes. 
We used the area under receiver operating curves (AUC) as
he main metric to evaluate the model performance on separat-
ng 1) housekeeping genes against common non-essential genes;
) common essential genes against common non-essential genes;
nd 3) pan-cancer oncogenes against pan-cancer tumour suppres-
or genes. The statistical signiﬁcance between two ROCs was de-
ermined using the DeLong test [29] . We also evaluated the hit
ates of these methods in identifying two well-known housekeep-
ng genes, GAPDH and ACTB , which are commonly used as loading
ontrols in western blot and qPCR experiments [30–32] . The hit
ate was deﬁned as the percentage of cell lines in which GAPDH
nd ACTB were identiﬁed as essential genes at various ranking cut-
ffs. Model predictions were also evaluated based on strictly stan-
ardized mean difference (SSMD) [33] , which measures how well
he true essential genes and non-essential genes are separated by
ach of the methods. 
In addition to essential genes that showed higher overall essen-
iality scores, we also determined cell-speciﬁc essential genes as
hose ranked at the top 100 for a given cancer cell line, whereas
heir average rankings across all the cell lines were lower than
0 0 0. In particular, we focused on the novel essential genes dis-
overed by the CES method alone, which did not show cell-speciﬁc
ene essentiality by either CRISPR or shRNA-based screen alone.
he novel cell-speciﬁc essential genes were plotted as a bipartite
etwork to show the interconnections of cancer dependency. 
.6. Survival analysis 
The newly identiﬁed cancer essential genes were tested for
ssociations with the disease-speciﬁc survival months of cancer
atients. To test the effect of AGR2 in ER-positive breast cancer
atients, we retrieved the breast cancer survival data from the
ETABRIC study [34] available from cBioPortal ( http://cbioportal.
rg/ ). Of 2509 samples, we took the samples that were labelled
s ER_IHC and ER_STATUS positive, and further removed sam-
les that were labelled as ‘Died of Other Causes’, resulting in a
nal set of 983 samples. Microarray-based gene expression and
opy number variation data for these samples were retrieved from
BioPortal. To test the effect of SRGN on the survival of AML
atients. We retrieved the patient clinical data from the Beat-
ML study [35] . Of the 451 patients included in the study, we
emoved samples that were diagnostic with cancers other than
Leukaemia’. For patients with more than one samples, we took
he earlier diagnostic samples. Furthermore, samples that were la-
elled with unknown or other causes of death were discarded, re-
ulting in a ﬁnal set of 297 samples. LogCPM-based gene expres-
ion data were retrieved from cBioPortal. Disease-speciﬁc survival
urves were empirically estimated using the Kaplan–Meier method
nd Log-rank test was used to determine the signiﬁcance of the
ifference. , Combined gene essentiality scoring improves the prediction of 
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Fig. 2. Limited consistency of CRISPR and shRNA-based gene essentiality scores across a total of 42 cancer cell lines. a. Between-screen consistency for each cell line was 
determined by Pearson correlation and mean squared error (MSE). The MSE for permutated CRISPR and shRNA essentiality scores is shown as the dashed line (MSE = 2.04). 
b. CRISPR and shRNA-based essentiality scores for the set of housekeeping genes compared to other genes. c. Pearson correlation between CRISPR and shRNA essentiality 
scores for the set of housekeeping genes compared to other genes. 
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m  . Results 
.1. Limited genome-scale consistency between CRISPR and shRNA 
creens 
To evaluate how the choice of technology affects gene essential-
ty scoring, we ﬁrst evaluated the correlations of gene essentiality
cores determined by CRISPR and shRNA screens for a given cancer
ell line. We found generally low levels of between-screen corre-
ations across all 42 cell lines, where 25 of them showed positive
ut moderate correlations (maximal correlation = 0.23), whereas 17
ell lines had negative correlations. The average between-screen
orrelation was 0.07, indicating a poor consistency of shRNA and
RISPR-based gene essentiality scores at the genome scale ( Fig. 2 a).
The HT29 cell line (colon cancer) showed the highest con-
istency with a between-screen correlation of 0.23. In contrast,Please cite this article as: W. Wang, A. Malyutina and A. Pessia et al.
cancer dependency maps, EBioMedicine, https://doi.org/10.1016/j.ebiome observed much poorer between-screen consistency for cell
ines PC3 (prostate cancer) and L33 (pancreatic cancer), where
he correlations dropped below zero. In general, we did not ob-
erve enrichment of certain tissue types in cell lines with higher
etween-screen correlations. However, 9 out of 10 leukaemia cell
ines showed moderately positive correlations ranging from 0.12
o 0.20, suggesting that leukaemia cells tend to respond similarly
o different screen technologies. On the other hand, the remaining
eukaemia cell line (K562) had a poor correlation of −0.01, which
as also replicated in a previous study [4] . We further tested the
ccuracy of using the shRNA score to predict the CRISPR score. The
ean squared errors (MSE) were similar to those for a permutated
rediction, conﬁrming the limited genome-scale consistency of the
wo screens for cancer cell lines in general ( Fig. 2 a). 
As we took the gene essentiality scores that were already sum-
arized over multiple sequence constructs for both the shRNA and, Combined gene essentiality scoring improves the prediction of 
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s  CRISPR screens, the limited consistency could not be explained
simply by the biases of certain sequence constructs that may
differ in their targeting eﬃcacy and off-target tendency. On the
other hand, we found that both shRNA and CRISPR screens pro-
vided lower essentiality scores (i.e. stronger gene essentiality) for
housekeeping genes ( n = 3804) compared to others (median score
−0.02 vs 0.14 for CRISPR screen and −0.08 vs . 0.09 for the shRNA
screen, respectively; Wilcoxon test p-value < 2e-16; Fig. 2 b), sug-
gesting the overall validity of the genome-wide functional screens
to detect true positive hits. For these housekeeping genes, the
between-screen correlations improved modestly, with an average
correlation of 0.10 versus 0.05 for the other genes ( Fig. 2 c). How-
ever, the variation of correlations across cell lines was also inﬂated
(variance of 0.016 versus 0.003 for the other genes). Notably, for
cell lines ( n = 13) with negative between-screen correlations, the
consistency for housekeeping genes became even worse, with an
average correlation of −0.026 compared to −0.018 for other genes.
Similar results were also found on the common essential gene set
and the PanCancer gene set (Supplementary Figure 2). These re-
sults implied that cancer essential genes did not necessarily show
higher consistency between the shRNA and CRISPR screens. 
3.2. CES improves the prediction of cancer essential genes 
Given the limited consistency observed between the shRNA and
CRISPR gene essentiality proﬁles, we developed a CES model that
considers both screening technologies for estimating gene essen-
tiality. More importantly, the CES model also included the molec-
ular features of cancer cells to derive a more accurate gene essen-
tiality estimation. Speciﬁcally, the CES score is a weighted average
of shRNA and CRISPR gene essentiality scores, where the molec-
ular features of cancer cells inﬂuence the weights determined by
the objective function that minimizes the sum of the squares of
CES and CRISPR scores (see Materials and Methods for details). 
We compared CES with baseline methods including SA, CES null ,
CES perm , as well as existing methods including CERES and DEME-
TER (see Materials and Methods for the description of these meth-
ods). The unadjusted shRNA and CRISPR essentiality scores were
also included in the comparison as baseline methods. To evaluate
the model performance, we used previously curated gold standards
on positive cases including a housekeeping gene set ( n = 3804), a
common essential gene set ( n = 360), and a PanCancer oncogene
set ( n = 31), as well as gold standards on negative cases including
a common non-essential gene set ( n = 927) and a PanCancer tu-
mour suppressor gene set ( n = 75). These gold-standard gene sets
have been manually curated and widely utilized for the evalua-
tion of functional screening results (e.g. [11,17,36–38] ) (Supplemen-
tary Tables 2–6). We found that the CES score outperformed other
scores in terms of classiﬁcation accuracy for all three cancer es-
sential gene sets ( Fig. 3 a-b, Supplementary Figure 3, Delong test,
p-values are reported in Supplementary Table 7). For example, the
area under the ROC curve (AUC) for CES on detecting housekeep-
ing genes was 0.906, compared to 0.732 for CERES and 0.634 for
DEMETER2 as the other top performing methods. As expected, the
SA, CES null , and CES perm models performed relatively poorly with an
AUC of 0.586, 0.596, and 0.604 separately, as these models did not
include molecular features to predict gene essentiality. The perfor-
mance of shRNA-based methods was generally worse than that of
CRISPR-based methods. Particularly, the AUC for DEMETER is just
below 0.5, suggesting that its performance is no different than a
random prediction. Similarly, CES also achieved the highest accu-
racy to detect the common essential genes (AUC = 0.971, Fig. 3 b)
and PanCancer genes (AUC = 0.702, Supplementary Figure 3). 
We also found that commonly known housekeeping genes were
more likely to be identiﬁed by CES than by other methods. For
example, GAPDH is a constitutively expressed gene that encodesPlease cite this article as: W. Wang, A. Malyutina and A. Pessia et al.
cancer dependency maps, EBioMedicine, https://doi.org/10.1016/j.ebiomhe enzyme for regulating cell energy metabolism, the inhibition of
hich leads to apoptosis. In our analysis, GAPDH was ranked in the
op 250 for 40 cell lines using CES scoring, whereas in most of the
ther scoring methods, the gene was essential in less than 20 cell
ines even with a much looser threshold of 10 0 0. Similar results
ere found for ACTB , which encodes a member of the highly con-
erved actin protein family, and is widely involved in cell motility,
tructure, integrity, and intercellular signalling [39] . As illustrated
n Fig. 3 c,d, GAPDH and ACTB were identiﬁed as cancer essential
enes more often by CES than by other methods at the given rank-
ng thresholds, resulting in the largest AUC for both genes (96.5%
nd 97.9% for GAPDH and ACTB , respectively). 
Furthermore, we evaluated the level of separation between
ancer essential and non-essential gene sets using strictly stan-
ardized mean difference (SSMD) [33] . Ideally, a scoring method
hat can better separate cancer essential genes from non-essential
enes should result in higher absolute values of SSMD. As shown
n Fig. 3 e, CES scores led to a much larger separation between the
ousekeeping genes and the non-essential genes, outperforming
ther scoring methods in all the available cell lines. For example,
ES increased by 85.5% on average of the absolute SSMD with ro-
ust improvement for all the cell lines compared to CERES, which
as the second-best method in terms of SSMD ( Fig. 3 e,f, Supple-
entary Table 8). In contrast, methods such as raw CRISPR scores
r DEMETER scores showed large variance in SSMD across different
ell lines, with SSMD even being positive in some cancer cells. We
lso found similar results using the common essential gene set and
he PanCancer gene set, although with less striking differences in
SMD (Supplementary Figure 4). Taken together, these results sug-
ested that CES can capture the true essential genes with superior
ccuracy compared to the state-of-the-art methods. 
.3. CES corrects screen-speciﬁc biases 
As shown in Fig. 2 a, the consistency of gene essentiality pro-
les between shRNA and CRISPR screens varied from moderate to
ow levels. Similar patterns were also observed for the subset of
ancer essential genes ( Fig. 2 c). Ideally, a cancer essential gene
hould show higher essentiality scores across multiple cell lines,
hereas a non-essential gene should be ranked at the bottom of
he list. We picked up the cell line (HT29), which shows the high-
st between-screen consistency, and then mapped the housekeep-
ng genes and non-essential genes on the scatter plot of the cell
ine average essentiality score versus the cell line speciﬁc essential-
ty score, determined by each of the methods ( Fig. 4 ). CES essen-
iality scores separated the housekeeping and non-essential genes
uﬃciently well. In contrast, there was a big overlap of density
stimates for the other methods, indicating that the shRNA and
RISPR screens are biased to detect certain subgroups of cancer
ssential genes more easily than the others. Similar patterns were
lso found for the common essential genes and PanCancer onco-
enes versus PanCancer tumour suppressor genes (Supplementary
igure 5). These results suggest that CES scores were able to cor-
ect screen-speciﬁc biases, resulting in more centralized and sep-
rated clusters for cancer essential genes and non-essential genes.
 similar pattern was observed in other cell lines, even with poor
etween-screen consistency such as the PC3 cell line (Supplemen-
ary Figure 6). These results suggested that the gene essentiality
cores estimated by CES are more robust for the screen-speciﬁc
xperimental biases that are otherwise diﬃcult to adjust using the
ther methods. 
Recent studies have shown that cancer cells may respond to ge-
etic perturbations introduced via shRNA or CRISPR-Cas9 by ac-
ivating distinct compensation mechanisms that involve different
ousekeeping genes [16,40] . As a result, housekeeping genes that
howed limited between-screen consistency may be involved in, Combined gene essentiality scoring improves the prediction of 
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Fig. 3. CES improves gene essentiality prediction on gold standard datasets. ROC curves were determined for each scoring method in detecting (a) housekeeping genes and 
(b) common essential genes. The AUC and their p-values can be found in Supplementary Table 7. The performance was illustrated using two well-known housekeeping genes 
including (c) GAPDH and (d) ACTB , where the fraction of cell lines in which the gene was identiﬁed as essential is shown as a function of the ranking threshold. Furthermore, 
the separation of gene essentiality scores for housekeeping genes and common non-essential genes was measured by the strictly standardized mean difference (SSMD), 
shown at (e) individual cell lines (ranked by SSMD of CES scores) and (f) averaged across all cell lines. Their p-values for median differences can be found in Supplementary 
Table 8. 
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s  hese compensation mechanisms that are speciﬁc to one screen
ut not the other. Therefore, analysing the between-screen consis-
ency of housekeeping genes may provide novel insights on path-
ays that tend to be affected by screen-speciﬁc compensation
echanisms. We focused on a subset of housekeeping genes that
howed signiﬁcant differences in shRNA-based essentiality scores
ersus CRISPR-based essentiality scores (two-group paired t -test, p-
alue < 0.05, Supplementary Table 9). We ranked these housekeep-
ng genes ( n = 1937) according to the difference between CRISPR
cores and shRNA scores and determined the biological pathways
nriched at the top or bottom ranking using the GSEA pre-ranked
ethod [41] . The top-ranking genes in general showed strong neg-
tive shRNA scores and close-to-zero CRISPR scores, suggesting its
elective sensitivity to shRNA perturbation but not CRISPR pertur-
ation. On the contrary, the bottom ranking genes showed selec-Please cite this article as: W. Wang, A. Malyutina and A. Pessia et al.
cancer dependency maps, EBioMedicine, https://doi.org/10.1016/j.ebiomive sensitivity to CRISPR perturbation. The gene set enrichment
nalyses showed distinct pathways that are enriched in CRISPR-
ensitive housekeeping genes versus shRNA-sensitive housekeep- 
ng genes ( Fig. 5 ). For example, CRISPR-sensitive genes are en-
iched mainly in DNA synthesis/metabolic (such as DNA template
ranscription initiation and elongation as well as DNA metabolic
athways) and DNA damage/repair related GO terms. CRISPR-Cas9
ased screening perturbs cancer cells by cutting the DNA and in-
ucing loss-of-function genetic mutations. These pathways, despite
eing important for cell survival, may be constitutively activated
ue to CRISPR-Cas9 perturbation, but not necessarily in shRNA-
ased screening, and may therefore explain the limited consis-
ency of gene essentiality proﬁles between them. In contrast, we
ound signiﬁcant enrichment for immune response pathways in
hRNA-sensitive genes, including WNT and tumour necrosis fac-, Combined gene essentiality scoring improves the prediction of 
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Fig. 4. Cell-line speciﬁc gene essentiality scores versus across-cell-line average scores in HT29 cells. CES showed the clearest separation of housekeeping genes and non- 
essential genes compared to the other methods, highlighted by the red and blue contours as the density estimates. 
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t  tor signalling pathways. These pathways tend to respond to shRNA
perturbations but not CRISPR perturbations. Interestingly, siRNA-
associated immune stimulation has been described previously [42] .
Taken together, these results suggest that the shRNA and CRISPR
screens may activate speciﬁc biological processes that are indepen-
dent of the true essentiality of the intended target genes. These
distinctive biological processes that are activated in one form of
genetic perturbation but not the other, may be worth further ex-
ploration with in-depth biological validation (Supplementary Ta-
bles 10,11). 
3.4. CES identiﬁes the molecular biomarkers for cancer essential 
genes 
For a given cancer essential gene, we also applied a linear re-
gression model to explain the CES using its molecular features
including genetic mutation, gene expression, and copy number.
A signiﬁcant molecular feature may therefore be considered as aPlease cite this article as: W. Wang, A. Malyutina and A. Pessia et al.
cancer dependency maps, EBioMedicine, https://doi.org/10.1016/j.ebiomiomarker for gene essentiality, for which the coeﬃcient can be
nterpreted as the weight of the biomarker. Note that a lower CES
ndicates a stronger gene essentiality by convention, a negative
eight therefore suggests a positive inﬂuence of the molecular fea-
ure contributing to the gene essentiality. 
We found that most of the cancer essential genes (i.e. house-
eeping genes, common essential genes and PanCancer onco-
enes) showed signiﬁcant weights (with nominal p-value < 0.05)
or copy number variation, accounting for 46.0% of all the sig-
iﬁcant weights, followed by microarray-based gene expression
31.9.%), RNA-Seq-based RPKM gene expression (17.7%), and muta-
ion (4.4%). The weights for the copy number feature are negative
 −0.53 on average), suggesting that for a given gene, the possibility
f the gene being essential increases with an increasing copy num-
er. Copy number alterations are known to be the most frequent
enetic changes in cancer cells [43] . We reasoned that gene copy
mpliﬁcation increases the chromosomal instability correlated with
he disease state and prognosis, resulting in the activation of genes, Combined gene essentiality scoring improves the prediction of 
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Fig. 5. Biological pathways that are enriched in (a) CRISPR-sensitive housekeeping genes and (b) shRNA-sensitive housekeeping genes. CRISPR-sensitive housekeeping genes 
are deﬁned as those that showed signiﬁcantly stronger gene essentiality in CRISPR screens versus shRNA screens, whereas shRNA-sensitive housekeeping genes are deﬁned 
oppositely. LogFDR is the log10 of probability that a gene set with a given enrichment score represents a false positive, determined using the GSEA method [41] . A higher 
–logFDR, i.e. a lower FDR indicates less false positive rate. 
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2  ith enhanced essentiality [44–46] . For example, oncogenes in-
luding MYC, KRAS, and CCND1 showed strong CES with increas-
ng copy numbers, corroborating the recent studies about cancer
ependency on these gene ampliﬁcations ( Fig. 6 a) [47] . In con-
rast, neither CRISPR nor shRNA-based methods could capture such
 pattern clearly ( Fig. 6 b,c). The weights of gene expression fea-
ures are also generally negative using microarray ( −0.62 on aver-
ge) and RPKM ( −0.46 on average), suggesting that if a gene is up-
egulated, it is more likely to be essential, which was also reported
n recent large-scale RNAi studies [17] . 
CRISPR screens tend to produce false positive estimates of gene
ssentiality for non-essential genes that are ampliﬁed in the same
egion with cancer essential genes [11] . Therefore, we also evalu-
ted whether CES tends to be affected by the same bias. We in-
estigated CES for cancer essential genes and their neighbouring
enes located in the same genomic regions. Speciﬁcally, for a given
ssential gene-neighbour gene pair, we measured the distance in
ase pairs as well as the difference between their CES. We found
ero correlation between the genetic distances and CES difference,
uggesting that the CES is unlikely to predict a higher gene es-
entiality simply due to copy number ampliﬁcation ( Fig. 6 d). For
xample, CCND1 is located in cytogenetic band 11q13, and is pre-
icted as the top essential gene among its neighbours located in
he same ampliﬁed region ( Fig. 6 e). Similarly, KRAS and MYC are
lso ranked at the top within highly ampliﬁed genomic regions
Supplementary Figure 7). At the genome-level, we found that CES
ould separate cancer essential genes from common non-essential
enes across all copy number levels ( Fig. 6 f,g and Supplementary
igure 8). These lines of evidence suggested that CES is not biased p  
Please cite this article as: W. Wang, A. Malyutina and A. Pessia et al.
cancer dependency maps, EBioMedicine, https://doi.org/10.1016/j.ebiomy copy number ampliﬁcation, which is known to be a confound-
ng factor in CRISPR-Cas9 screens [9,12,48] . 
Despite the relatively low number of signiﬁcant coeﬃcients for
utation features, CES recapitulated the well-known mutation de-
endency for multiple oncogenes. We ranked the genes by the
igniﬁcance of their mutation weights and found the top three
enes being key components of the RAS family including NRAS
estimate = −0.14, p-value = 5.61e-10), KRAS (estimate = −0.09, p-
alue = 1.47e-7) and BRAF (estimate = −0.06, p-value = 1.18e-5). For
xample, CES ranked NRAS at the top in two AML cell lines in-
luding THP1 and HL60, where NRAS is highly mutated with 15-
nd 21-fold greater frequency than the average. This suggested
hat NRAS mutation might play a crucial role in the proliferation
nd survival of AML. Indeed, oncogenic NRAS mutations are highly
revalent in AML patients [49] and MEK inhibitors targeting onco-
enic N-Ras signalling are currently under clinical trials for AML
atients [50] . Taken together, the regression of CES on molecu-
ar features may provide functional links between the genotype-
henotype of cancer essential genes that may be worth exploring
s biomarkers and drug targets. 
.5. CES identiﬁes cell-speciﬁc gene essentiality 
Finally, we utilized the CES to identify cell-speciﬁc essential
enes, deﬁned as genes ranked in the top 100 for a given can-
er cell line, while their overall rankings across all cell lines went
elow 50 0 0. Altogether 219 genes for the 41 cell lines, including
87 cell-gene pairs were detected (Supplementary Figure 9). In
articular, we were interested in novel essential genes discovered, Combined gene essentiality scoring improves the prediction of 
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Fig. 6. The predicted CES essentiality in genomic ampliﬁed regions. (a–c) Increased essentiality driven by a higher copy number in oncogenes KRAS, MYC , and CCND1 , 
captured by CES but not by CRISPR or shRNA scores. (d) Difference of CES for cancer essential genes and their neighbouring genes does not correlate with their genomic 
distances. (e) CCND1 was predicted as a top essential gene by CES from the ampliﬁed 11q13 genomic region in cell line A673. (f,g) CES separates housekeeping genes (f) and 
common essential genes (g) from non-essential genes under the same scenario of copy number quantiles. 
Please cite this article as: W. Wang, A. Malyutina and A. Pessia et al., Combined gene essentiality scoring improves the prediction of 
cancer dependency maps, EBioMedicine, https://doi.org/10.1016/j.ebiom.2019.10.051 
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Fig. 7. The novel cell-speciﬁc essential genes detected exclusively by CES. Round nodes are cell lines and square nodes are genes. 
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9  y the CES method but not by the CRISPR and the shRNA-based
ethods. Therefore, we focused on the subset of cell-speciﬁc genes
hat ranked below 20 0 0 in both CRISPR and shRNA-based scoring.
ltogether, 68 such novel essential genes were identiﬁed for 29
ell lines, for which the cancer dependency network is shown in
ig. 7 . We reasoned that cell-speciﬁc essential genes should gener-
lly have higher expressions in a cell-speciﬁc manner as well. In-
eed, the expression of essential genes in these cell lines is signif-
cantly higher than that of other cell lines (average rank 6.07 vs .
4.70, p -value < 2.2e-16 for RNA-seq based expression; average
ank 5.46 vs . 25.66, p-value < 2.2e-16 for microarray based expres-
ion, Wilcoxon rank sum test). 
The majority of the genes were essential in only one cell line
y the cell-speciﬁc selection criteria. For example, AGR2 has been
dentiﬁed by CES as an essential gene for the T47D cell line (breast
ancer) but not others. AGR2 has been reported to play a critical
ole in oestrogen receptor (ER) positive breast cancer development
51] . In contrast, both the CRISPR and shRNA screens failed to iden-
ify AGR2 as an essential gene for the T47D cell line (essential-Please cite this article as: W. Wang, A. Malyutina and A. Pessia et al.
cancer dependency maps, EBioMedicine, https://doi.org/10.1016/j.ebiomty score = 0.24 and 0.35, respectively). However, certain essential
enes were shared by multiple cell lines, suggesting an extended
evel of essential gene speciﬁcity for a group of cancer cell lines,
hich might allow them to be used as predictive biomarkers for
atient stratiﬁcation. For example, SRGN that encodes a hematopoi-
tic cell granule proteoglycan, has been identiﬁed by CES as a
ell-speciﬁc essential gene for eight leukaemia cell lines, of which
even were not detected by CRISPR or shRNA-screens alone, in-
luding MOLM13, MV411, MONOMAC1, OCIAML2, OCIAML3, OCI-
ML5, and THP1. Interestingly, all these cell lines belong to the
ML (acute myeloid leukaemia) subtype, suggesting the potential
f using SRGN as a prognostic biomarker or drug target for AML.
ndeed, as shown in Supplementary Figure 10, SRGN expression
as higher in these AML cell lines. Using patient data from the
ETABRIC and BeatAML studies (see Methods for details), we fur-
her showed that AGR2 upregulation is predictive of poor survival
n ER-positive breast cancer patients, and that SRGN upregulation
s associated with AML prognosis ( Fig. 8 ). More speciﬁcally, for the
83 ER-positive samples in the METABRIC study, we found that, Combined gene essentiality scoring improves the prediction of 
.2019.10.051 
12 W. Wang, A. Malyutina and A. Pessia et al. / EBioMedicine xxx (xxxx) xxx 
ARTICLE IN PRESS 
JID: EBIOM [m5G; November 12, 2019;16:8 ] 
Fig. 8. Survival analysis for the novel cancer essential genes including a) AGR2 in ER-positive breast cancer patients and b) SRGN in AML patients. Disease-speciﬁc survival 
curves were empirically estimated using the Kaplan–Meier method and Log-rank test was used to determine the signiﬁcance of the difference. 
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t  
s  samples ( n = 38) with higher gene expression (EXP z-score > 2)
or copy number ampliﬁcation (CNV > 1) showed a signiﬁcantly
poor prognosis (median disease-speciﬁc survival 123 months vs.
226 months, log-rank test, p = 0.02) compared to other samples;
For the 297 AML samples in the BeatAML study, we found that
patients with high SRGN expression (logCPM median z-score > 0,
n = 150) had signiﬁcantly poor survival compared to others (me-
dian disease-speciﬁc survival 14.3 months vs. 20.8 months, log-
rank test, p = 0.05). These results suggested the clinical potential
and beneﬁt of targeting these essential genes for speciﬁc patient
groups. The actual functions of AGR2 and SRGN , together with
other novel essential genes that were found speciﬁcally for spe-
ciﬁc groups of cell lines, might be worth further investigation to
facilitate patient stratiﬁcation and drug discovery in personalized
medicine. 
4. Discussion 
Loss-of-function genetic screens with shRNA- and CRISPR-based
techniques have been commonly utilized for studying cancer de-
pendency at the genome-level, although questions remain on how
to eﬃciently leverage these datasets to generate more consistent
gene essentiality proﬁles for a given cancer sample. A recent side-
by-side comparison in the K562 cell line (leukaemia) demonstrated
a lack of consistency for the essential genes identiﬁed by these two
screen techniques [4] . In this study, we performed a more system-
atic comparison using a panel of 42 cancer cell lines representing
ten tissue types and conﬁrmed the limited between-screen con-
sistency across various cellular contexts. Reasons for this limited
consistency might vary and may depend on confounding factors
related to experimental design, as well as inherent biases that are
speciﬁc to one screen technology but not the other. For example,
recent studies showed that CRISPR screens may erroneously iden-
tify genes in copy-number-ampliﬁed regions as essential, as the
DNA damage response and cell cycle arrest may be triggered by
the CRISPR-Cas9 process independently of the essentiality of the
targeting genes [2] . It has also been shown that shRNA screens may
be less likely to detect essential genes expressed at low levels [20] .
In our data analysis, we also found that housekeeping genes that
are involved in certain biological pathways tend to respond differ-
ently to CRISPR and shRNA perturbation ( Fig. 5 ). These and other
confounding factors may contribute to the limited between-screenPlease cite this article as: W. Wang, A. Malyutina and A. Pessia et al.
cancer dependency maps, EBioMedicine, https://doi.org/10.1016/j.ebiomonsistency, which may pose a challenge to estimate true gene es-
entiality. 
To improve the accuracy of gene essentiality estimation, many
omputational methods have been developed for genetic screens
sing single technologies, whereas there is a lack of integra-
ive methods to combine the gene essentiality proﬁles from both
RISPR and shRNA screens. Furthermore, the molecular features of
ancer cells that are known to play important roles in determining
he function of genes have not been effectively considered when
stimating gene essentiality. Following this line, we proposed a
ata integration model called Combined Essentiality Score (CES) to
ntegrate the genetic essentiality proﬁles from these two screen-
ng techniques, while accounting for the molecular signatures of
ancer cells. We showed that the CES model improved the pre-
iction of multiple reference sets of cancer essential genes and
on-essential genes, compared to existing computational methods
ncluding CERES and DEMETER1/2. Furthermore, CES was able to
orrect the screen-speciﬁc biases, suggesting that the CES could
e used as a more reliable metric for estimating true essential-
ty. The CES method differs from existing computational methods
hat usually consider one type of genetic screen. Rather, CES tries
o integrate the gene essentiality proﬁles from both CRISPR and
hRNA screens and improves gene essentiality estimation by incor-
orating molecular features including mutation, gene expression,
nd copy number variation. In contrast, CERES and DEMETER1/2
ocused mainly on off-target correction, but rarely considered the
ifferential responses to CRISPR and shRNA perturbations, which
ould explain the less accurate prediction performance compared
o CES. Furthermore, the linear structure of CES allows the quan-
iﬁcation of molecular feature effects on gene essentiality and may
hus may provide clues about why a given gene is essential. We
emonstrate several case studies where the identiﬁed cancer es-
ential genes indeed make biological sense that may warrant fur-
her experimental validation. Importantly, we assumed that inter-
ctions between molecular features, the raw CRISPR and shRNA
cores, and true essentiality scores are rather complex and most
ikely gene- and cancer-speciﬁc. Therefore, we reported the source
ode and CES scores to allow cancer researchers to further test the
alidity and biological rationale of CES at the genome and pan-
ancer level. 
We collected a total of 42 cell lines from recent publications
o demonstrate our model. It should be noted that several large-
cale projects including Achilles [12] and DepMap [15] are con-, Combined gene essentiality scoring improves the prediction of 
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 inuously generating genome-wide functional genetic screen data
or more cancer cell lines. The accumulating genome-wide func-
ional screening data are expected to improve the scope of the
ES model. On the other hand, the CES model currently takes
ene level essentiality scores as inputs, because gene-level data
re more commonly available from existing studies. Data pre-
rocessing procedures from the shRNA or sgRNA level to gene level
ay affect the CRISPR and shRNA-based gene essentiality estima-
ion and may thus affect the CES. Given that high quality shRNA
evel or sgRNA level data have been made available recently, direct
odelling of gene essentiality proﬁles from sgRNA and shRNA level
ata may be worth exploring as a future step. 
Our method provides a novel perspective to explore the large
eature space for cancer genes, allowing improved prediction
f essential genes and their functional annotation in individual
ell lines. Effective integration of functional and molecular data
ight provide important clues for drug discovery in personalized
edicine. For example, we utilized the mutation status of genes as
 predictor of CES score. The correlation of CES score with muta-
ion status might be indicative of whether such a mutation is an
ctivating or inactivating mutation. However, more experimental
alidation is required for evaluating its potential as a drug target.
lthough we have focused on high-throughput functional genetic
creens that are largely measuring cell growth in this study, the
ES modelling strategy itself is applicable to interrogate genes that
re essential for other cellular phenotypes and functions. For ex-
mple, recent technologies in single-cell sequencing have enabled
he testing of multiple phenotypes for speciﬁc gene depletions in a
ooled fashion (e.g. CROP-seq and Perturb-seq) and we expect that
ur method can be also applied there [52] . In addition to human
ancer cell lines that were studied most extensively, limited phe-
otypic consistencies were also observed in other model organisms
ncluding mouse and zebraﬁsh [53,54] . We foresee that the CES
odel can be extended to improve the estimation of genetic de-
endency in cancer cell lines as well as in other model organisms. 
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